Clinical trials
Cancer clinical trials
Below are recruiting cancer clinical trials, each written for real people, not researchers. We’re tracking 12,865 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07171528RecruitingPhase 2
Surgery after chemo for recurrent ovarian cancer
This trial is for people with recurrent ovarian cancer whose disease came back more than 6 months after platinum chemo. It tests whether removing the recurrent tumor with surgery (after more chemo) can help—even if surgery wasn't an option before.
Goyang-si, Gyeonggi-doAges 19–80 - NCT07166094RecruitingPhase 3
Rina-S vs standard therapy for advanced endometrial cancer
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
Mobile, AlabamaAges 18 years+ - NCT07167381Recruiting
Tumor testing to find cancer treatments for Florida patients
This study tests your tumor sample to find which drugs might work best for your cancer. It is for both children and adults whose cancer has come back or not responded to treatment, and who have already tried at least one standard therapy.
Miami, FloridaAges Any age - NCT07167446RecruitingEarly Phase 1
CBD to prevent nerve damage from oxaliplatin in colorectal cancer
This trial tests if cannabidiol (CBD) can prevent nerve damage (neuropathy) caused by the chemotherapy drug oxaliplatin. If you have colorectal cancer that has spread or cannot be removed by surgery and you are about to start oxaliplatin, you may be able to join.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07173270Recruiting
Improving oral health in head and neck cancer survivors
This trial aims to improve oral health in people being treated for head and neck cancer. If you are receiving radiation therapy, this study may help manage side effects and keep your mouth healthier.
UppsalaAges 18 years+ - NCT07167056Recruiting
AI chatbot to improve quality of life in cancer patients
This trial tests whether an AI-powered chatbot can help people with cancer feel better emotionally and improve their quality of life. You can join if you are currently in cancer treatment, feeling distressed, and have a smartphone.
Weston, FloridaAges 18 years+ - NCT07166003Recruiting
Immunotherapy before surgery for lung cancer
This trial tests whether giving immunotherapy before surgery helps people with lung cancer. It is for patients who have already started this treatment and are otherwise healthy.
BeijingAges 18–79 - NCT07168616Recruiting
PSMA PET imaging for active surveillance in low-risk prostate cancer
This study uses a special imaging test (PSMA PET/CT) to better see if men with low-risk prostate cancer are good candidates for active surveillance (monitoring instead of immediate treatment). It helps doctors decide if watching the cancer closely is safe.
Istanbul, TurkeyAges 18 years+ - NCT02047994RecruitingPhase 4
Testing and treatment for H. pylori to prevent stomach cancer death
This trial studies whether testing for an infection called H. pylori and using simple blood/screening tests (pepsinogen testing) can help prevent stomach cancer and reduce stomach-cancer-related deaths. You would be followed for health outcomes to see if the approach works better than standard care.
RigaAges 40–64 - NCT05621837Recruiting
Biomarker study to guide treatment for several advanced cancers
This study measures how strongly your immune system is being suppressed and uses that information to help personalize cancer treatment. It mainly looks at people with certain advanced cancers and needs tumor tissue and follow-up to check possible immune-related markers.
MilanAges 18–90 - NCT07155200RecruitingPhase 1/Phase 2
Study of a new drug combined with irinotecan for small cell lung cancer
This study tests a new drug (cirtuvivint) combined with irinotecan, a common chemotherapy, for people whose small cell lung cancer has progressed after at least one prior treatment. The goal is to see if the combination helps control the cancer and whether it is safe.
St Louis, MissouriAges 18 years+ - NCT07162714RecruitingPhase 2
Short-course radiation plus AK112 for mismatch repair-proficient rectal cancer
This trial tests a new immunotherapy drug (AK112) given after a short course of radiation. It is for people with a specific type of mid-low rectal cancer that has not spread and has not been treated before.
Hangzhou, ZhejiangAges 18–75 - NCT07164456Recruiting
Family support program for Black prostate cancer survivors
This study tests a family-based program to help Black prostate cancer survivors and their caregivers live healthier. You and a family member will join together to improve diet, activity, and well-being.
Houston, TexasAges 18 years+ - NCT07156058Recruiting
Personalized therapy after surgery for bile duct cancer
This trial uses a test called MiniPDX, which grows a tiny sample of your tumor in mice to see which drugs work best. After your surgery, you'll receive chemotherapy chosen specifically for your cancer to help prevent it from coming back.
BeijingAges 18 years+ - NCT07159451RecruitingPhase 2
Elacestrant for premenopausal women with early breast cancer
This trial tests a new hormone therapy pill, elacestrant, given alone or with another drug to suppress ovarian function before surgery. It's for premenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see if it can shrink the tumor.
VillejuifAges 18 years+ - NCT07161713Recruiting
Relaxation and stress reduction study for cancer survivors
This study is testing whether relaxation and stress reduction techniques can help your body heal at a cellular level. If you are a cancer survivor who finished treatment at least 6 months ago, you may be able to join.
Stony Brook, New YorkAges 18 years+ - NCT03144648Recruiting
Study of breast cancer subtypes in premenopausal women in Latin America
This study looks at different biological “subtypes” of breast cancer in women who are still having periods. It helps researchers understand the cancer type and may guide more personalized care in the future.
BarretosAges 20–45 - NCT03893929Recruiting
Test new markers to help diagnose prostate cancer
This study looks for new biological markers in men to improve how prostate cancer is diagnosed and followed. If you have signs that might be prostate cancer, your tests may help researchers find better clues for future care.
ShatinAges 18 years+ - NCT07150208RecruitingPhase 2
T-DXd with or without Avastin for HER2-low breast cancer that spread to the brain
This trial tests a combination of two targeted drugs (T-DXd and bevacizumab) for people with HER2-low breast cancer that has spread to the brain. It aims to see if adding bevacizumab helps the main drug work better against brain metastases.
ShanghaiAges 18–70 - NCT07146568Recruiting
Pink and Pearl Lung Cancer Screening Study
This trial is testing a program called the Pink and Pearl Campaign to help more people get screened for lung cancer. If you're getting a mammogram at Christian Hospital and are between 50 and 80, you might be able to join.
St Louis, MissouriAges 20 years+ - NCT07154563Recruiting
Quick test for breast cancer spread to lymph nodes using a new probe
This trial uses a special probe that lights up cancer cells to quickly check if breast cancer has spread to nearby lymph nodes. It may help doctors decide how much surgery is needed.
Kunming, YunnanAges 18–75 - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT07152782RecruitingPhase 2
T-DXd with or without neratinib for HER2+ breast cancer brain metastases
This trial tests whether adding neratinib to T-DXd (trastuzumab deruxtecan) works better than T-DXd alone for women with HER2-positive breast cancer that has spread to the brain. It is for those who have not had these specific drugs before.
ShanghaiAges 18–70 - NCT07149090RecruitingPhase 1/Phase 2
Lenvatinib, Nivolumab, and Chemo in Stomach Cancer with Ascites
This trial tests a combination of two drugs (lenvatinib and nivolumab) plus chemotherapy for people with advanced stomach cancer that has caused fluid buildup in the belly. The goal is to see if this combination can help shrink the cancer and reduce the fluid.
SeoulAges 19 years+
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer?
- Yes. Clin2 currently lists 12,865 recruiting cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.